Concepts (82)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myelodysplastic Syndromes | 6 | 2004 | 10 | 0.250 |
Why?
|
| Thrombosis | 1 | 2021 | 33 | 0.170 |
Why?
|
| Thalidomide | 2 | 2004 | 3 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2004 | 99 | 0.080 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2008 | 7 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2004 | 86 | 0.060 |
Why?
|
| Proto-Oncogenes | 1 | 2004 | 3 | 0.050 |
Why?
|
| Arsenicals | 1 | 2004 | 6 | 0.050 |
Why?
|
| Oxides | 1 | 2004 | 7 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 95 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 42 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2004 | 105 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 151 | 0.050 |
Why?
|
| Humans | 10 | 2021 | 12240 | 0.050 |
Why?
|
| Apoptosis | 3 | 1999 | 105 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2001 | 22 | 0.040 |
Why?
|
| Anemia | 1 | 2001 | 15 | 0.040 |
Why?
|
| Bone Marrow | 2 | 2001 | 35 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2000 | 20 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 423 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2000 | 105 | 0.040 |
Why?
|
| Ecchymosis | 1 | 1998 | 2 | 0.030 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 1998 | 2 | 0.030 |
Why?
|
| Tretinoin | 1 | 1998 | 8 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 1998 | 9 | 0.030 |
Why?
|
| Male | 6 | 2008 | 6815 | 0.030 |
Why?
|
| Pilot Projects | 3 | 2004 | 214 | 0.030 |
Why?
|
| Idoxuridine | 1 | 1997 | 1 | 0.030 |
Why?
|
| Bromodeoxyuridine | 1 | 1997 | 2 | 0.030 |
Why?
|
| Middle Aged | 5 | 2008 | 4043 | 0.030 |
Why?
|
| Cell Cycle | 1 | 1997 | 17 | 0.030 |
Why?
|
| Aged | 5 | 2004 | 4000 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 1996 | 9 | 0.030 |
Why?
|
| Endopeptidases | 1 | 1996 | 12 | 0.030 |
Why?
|
| Adult | 2 | 2021 | 3557 | 0.030 |
Why?
|
| Female | 5 | 2008 | 6974 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2008 | 2152 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2004 | 1478 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2008 | 28 | 0.020 |
Why?
|
| Anemia, Refractory | 1 | 2004 | 1 | 0.010 |
Why?
|
| Pancytopenia | 1 | 2004 | 1 | 0.010 |
Why?
|
| Cytogenetic Analysis | 1 | 2004 | 1 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2004 | 12 | 0.010 |
Why?
|
| Infliximab | 1 | 2004 | 7 | 0.010 |
Why?
|
| Remission Induction | 1 | 2004 | 45 | 0.010 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2004 | 2 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2004 | 13 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 2004 | 10 | 0.010 |
Why?
|
| Spleen | 1 | 2004 | 15 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 68 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 76 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 61 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2004 | 75 | 0.010 |
Why?
|
| Disease Progression | 1 | 2004 | 290 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2001 | 7 | 0.010 |
Why?
|
| Hematopoiesis | 1 | 2001 | 5 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2001 | 9 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2001 | 14 | 0.010 |
Why?
|
| Risk Factors | 1 | 2004 | 1049 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 2000 | 2 | 0.010 |
Why?
|
| Amifostine | 1 | 2000 | 2 | 0.010 |
Why?
|
| Cytarabine | 1 | 2000 | 5 | 0.010 |
Why?
|
| Radiation-Protective Agents | 1 | 2000 | 3 | 0.010 |
Why?
|
| Karyotyping | 1 | 1999 | 7 | 0.010 |
Why?
|
| S Phase | 1 | 1999 | 3 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 1999 | 8 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1999 | 8 | 0.010 |
Why?
|
| Prognosis | 1 | 2000 | 363 | 0.010 |
Why?
|
| Macrophages | 1 | 1999 | 38 | 0.010 |
Why?
|
| Cytokines | 1 | 1999 | 107 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1998 | 151 | 0.010 |
Why?
|
| DNA | 1 | 1997 | 57 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1996 | 1 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 1996 | 7 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 1996 | 4 | 0.010 |
Why?
|
| Caspase 1 | 1 | 1996 | 4 | 0.010 |
Why?
|
| DNA Replication | 1 | 1996 | 4 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1996 | 14 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 9 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1996 | 23 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1996 | 20 | 0.010 |
Why?
|
| Adolescent | 1 | 1999 | 989 | 0.010 |
Why?
|